Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.47 |
| ▸ | XDH | P47989 | 4/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25611309 | 0.90 | USP30 (0.49) | USP30XDHEGLN2 | |
| SCHEMBL25611033 | 0.89 | USP30 (0.48) | USP30XDHS1PR1S1PR5UCHL1 | |
| SCHEMBL25610970 | 0.85 | USP30 (0.45) | USP30XDHS1PR1S1PR5UCHL1 | |
| SCHEMBL25610969 | 0.85 | USP30 (0.45) | USP30XDHS1PR1S1PR5UCHL1 | |
| SCHEMBL25611032 | 0.84 | USP30 (0.43) | USP30XDHS1PR1S1PR5UCHL1 | |
| SCHEMBL25613444 | 0.82 | XDH (0.43) | USP30XDHS1PR1S1PR5UCHL1 | |
| SCHEMBL25611227 | 0.81 | UCHL1 (0.41) | USP30XDHS1PR1S1PR5UCHL1 | |
| SCHEMBL25611030 | 0.81 | XDH (0.38) | USP30XDHS1PR1S1PR5UCHL1 | |
| SCHEMBL25610836 | 0.80 | ALDH1A1 (0.48) | USP30 | |
| SCHEMBL25605336 | 0.79 | MKNK1 (0.59) | USP30XDHS1PR1S1PR5UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |